| Ytd | -59.03% | |
| 1y | -34.13% |
| Open | 2.20 | Prev Close | 2.22 | Low | 2.20 | High | 2.38 | Mkt Cap | 396.19M |
| Vol | 3.97M | Avg Vol | 3.63M | EPS | -0.40 | P/E | -5.50 | Forward P/E | -10.86 |
| Beta | 1.30 | Short Ratio | 12.39 | Inst. Own | 88.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 2.10 | 200-d Avg | 4.15 | 1yr Est | 13.64 |
CMPX News
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data fo
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical compa
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stag
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff.
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 S
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday.
Tuesday's session saw 729 companies set new 52-week lows.